UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,049	02/26/2007	Nathalie Guennouni	022702-000149	4267
21839 7590 02/29/2008 BUCHANAN, INGERSOLL & ROONEY PC			EXAMINER	
POST OFFICE	BOX 1404	LOEWE, ROBERT S		
ALEXANDRIA, VA 22313-1404			ART UNIT	PAPER NUMBER
			1796	
			NOTIFICATION DATE	DELIVERY MODE
			02/29/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ADIPFDD@bipc.com

	Application No.	Applicant(s)			
	10/562,049	GUENNOUNI ET AL.			
Office Action Summary	Examiner	Art Unit			
	Robert Loewe	1796			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>23 December</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 11-20 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 11-20 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access	vn from consideration. relection requirement. r. epted or b) □ objected to by the E				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 12/23/05.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Claim Interpretation

For purposes of further examination, the limitation "microgram atoms" of instant claims

11 and 12 have been interpreted to mean or be equivalent to micromoles. The Examiner notes

that while the term microgram atoms is not incorrect, it is not as widely used as the more familiar

term micromoles.

Claim Objections

Claims 11, 13 and 17 are objected to because of the presence of underlined text.

Appropriate correction is required.

Claim 13 is objected to because of the following informalities: the limitation "with or

without π participation" does not appear to further limit what ligand(s) L may be. Either a ligand

allows for π -participation or it does not. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the

subject matter which the applicant regards as his invention.

Claims 16-19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for

failing to particularly point out and distinctly claim the subject matter which applicant regards as

the invention. Specifically, claim 16 recites the limitations "POS A' or A" " in line 5 and "B' or

B" " in line 6. There is insufficient antecedent basis these limitations in the claim. Claims 16-19

are further rejected because the limitation "in a final stage 3" is not defined. For purposes of suggestion, the final 3 lines of instant claim 16 does not appear to further limit the process of instant claim 16 and could be removed. Appropriate correction is required.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 11 and 13-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Dalbe et al. (WO-2002/083778). For convenience, an English translation of this publication provided by the McElroy Translation Company will be relied upon. All citations incorporated herein refer to the English translation.

Art Unit: 1796

Claims 11 and 14-15: Dalbe et al. teaches a single-component polyorganosiloxane composition which is substantially equivalent to instant claim 11. Specifically, Dalbe et al. teaches that the composition comprises a polysiloxane which satisfies the structural and physical limitations of formula I of instant claim 11 (pages 9-10), a polyorganosiloxane resin which may be incorporated in the claimed amounts of instant claim 11 (p. 10), a crosslinking agent which satisfies the structural limitations of formula (II) of instant claim 11 (p. 10), a functionalization catalyst (bottom of p. 18-top of p. 19), a primary aliphatic alcohol (p. 22), at least one unreactive linear polysiloxane which satisfies the structural limitations of formula (III) of instant claim 11 (bottom of p. 10), at least one inorganic filler (p. 11), an auxiliary agent (p. 11). Dalbe et al. therefore explicitly teaches components (i)-(8i) of instant claim 11.

Dalbe et al. further teaches that an effective amount of component (9i) of instant claim 11 is added to the composition. With regards to parameters α and γ, Dalbe et al. teaches that the crosslinking/curing catalyst may be chosen from titanium organic complexes (M1 of instant claim 11), or metal salts, particularly metal carboxylates of tin, **zinc**, iron, lead, barium, manganese, zirconium, and **mixtures** thereof (M2 of instant claim 11) (p. 11; bottom of p. 13-top of p. 14; top of p. 22). More specifically, Dalbe et al. further teaches that the crosslinking/hardening catalyst consists of a metal carboxylate, including zinc octoate (M1 of instant claim 11) (top of p. 22) **and/or** a titanium organic derivative (M2 of instant claim 11) (top of p. 14). While Dalbe et al. does not explicitly teach ratios of M1 and M2 which may be employed, the teaching of "and/or" by Dalbe et al. does suggest to a person having ordinary skill in the art that a mixture of the metal carboxylate catalysts and titanium catalysts can be added together. The most obvious ratio which would be immediately envisaged would be a mixture of

Art Unit: 1796

zinc octoate and an organic titanium derivative in a 1:1 ratio. Further, the range of instant claim 11 of from 5 to 95% is so broad that nearly any selection of a catalyst mixture would encompass this range. Therefore, parameters α and γ are effectively taught by Dalbe et al. Further, a person having ordinary skill in the art would have been motivated to adjust the ratios of curing catalysts M1 and M2 in order to optimize the final properties of the composition, in light of the teachings of Dalbe et al.

With regards to parameter β , Dalbe et al. teaches that the catalyst can be added in a suitable amount, and further teaches this amount can be from 0.3-5 parts by weight based on the total number of parts of the composition. It is unclear whether Dalbe et al. explicitly teaches parameter β because of the number of variables that must be considered when comparing Dalbe et al. to instant claim 11. Specifically, the total parts of the compositions of Dalbe can be as low as ~ 105 total parts up to ~ 260 parts by weight (p. 22) which can have a large effect on the total parts by weight of catalyst. Further, Dalbe et al. teaches several catalysts which can have molecular weights as low as 171 (for example Ti(OMe)₄) up to above 1000 [for example Ti[(OCH₂CH₂)₂OC₁₂H₂₅]₄]; this range of catalyst molecular weight will also have a significant effect of the total amount of catalyst that is added on a microgram.atom (micromole) basis. While Dalbe et al. does not clearly teach that the catalyst system can be employed in the manner presented by parameter β, the amount of added catalyst is a result-effective variable. The courts have stated that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art (i.e., does not require undue experimentation). In re Aller, 105 USPQ 233. "Discovering an optimum value of a result effective variable involves only routine skill in the art." In re Boesch, 617 F.2d 272, 205 USPQ

Page 6

Art Unit: 1796

215 (CCPA 1980). Note too MPEP 2144.05 which states that "differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical". In the instant case, a person having ordinary skill in the art would have found it obvious to adjust the amount of the catalyst system as taught by Dalbe et al. and would have been motivated to do so in order to optimize the composition in terms of both economy (titanium catalysts are expensive for example) and optimization of the final physical properties.

Claim 13: Dalbe et al. further teaches that M1 can have the structural limitations of formula (V) of instant claim 13 and M2 can have the structural limitations of formulae (VI) and (VII) of instant claim 13 (pages 14, 21-22 and 35).

Claim 16: Dalbe et al. explicitly teaches that process for the preparation of the single component composition of instant claim 11 following the process of instant claim 16 (pages 28, preparation E).

Claims 17-18: Dalbe et al. further teaches that the hydroxylated precursor of instant claims 17 and 18 (p. 12 and p. 28, preparation E).

Claim 19: Dalbe et al. further teaches the functionalization catalysts of instant claim 19 (top of p. 19 and p. 28, preparation E).

Claim 20: Dalbe et al. teaches a non-yellowing elastomner composition capable of adhering to various substrates (p. 31).

Allowable Subject Matter

Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Specifically, Dalbe et al., which is believed to be the closest prior art reference, does not explicitly teach a binary curing catalyst system wherein parameter γ falls in the range of instant claim 12 (10-45%). It is believed that such a ratio would have been unobvious to a person having ordinary skill in the art given only the teaching that a mixture of two catalysts may be employed.

Relevant Art Cited

The prior art made of record and not relied upon but is considered pertinent to applicants disclosure can be found on the attached PTO-892 form.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Loewe whose telephone number is (571) 270-3298. The examiner can normally be reached on Monday through Friday from 5:30 AM to 3:00 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Randy Gulakowski can be reached on (571) 272-1302. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

Application/Control Number: 10/562,049 Page 8

Art Unit: 1796

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/R. L./ Examiner, Art Unit 1796 11-Jan-08

/Randy Gulakowski/

Supervisory Patent Examiner, Art Unit 1796